Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in real-world settings versus what is reported in clinical trials, likely because patients discontinue treatment or use lower maintenance dosages. ( Obesity )

In a large meta-analysis of randomized trials, gut microbiome-targeted therapies modestly improved glucometabolic parameters in people with type 2 diabetes. ( Journal of Clinical Endocrinology & Metabolism )

The Endocrine Society endorsed the bipartisan Treat and Reduce Obesity Act (TROA) , aimed to ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications.

U.K. regulators issued new guidance warning against the use of GLP-1 agonists during pregnancy; patients on tir

See Full Page